Adepa Biosciences
Category: Therapeutics
Campus: Ithaca
Incubator:
Adepa Biosciences (formerly Vernx Biotechnology) is developing a range of nutrition products using branched fatty acids (BCFA) for multiple uses: to improve gastrointestinal health in pre-mature and non-premature infants, as a nutritional supplement for adults, and for eventual therapeutic use.
Location: New South Wales, Australia
Foundation Cornell Technology Licensed: 2016
AffyImmune Therapeutics
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
AffyImmune is an immuno-oncology company that develops T cell products for cancer therapy. The company was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors. The company has two products in the pipeline, and are ready to commence clinical trials in 2018
Location: Natick, MA
Foundation Cornell Technology Licensed: 2017
Akelos, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Akelos Inc. is a biopharmaceutical clinical company developing novel non-opioid, anti-hyperalgesic drugs for the treatment of neuropathic pain. Their compounds are intended to selectively and potently inhibit HCN1 channel activity to limit pain.
Location: New York, New York
Foundation Cornell Technology Licensed: 2018
Angiocrine Bioscience, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Angiocrine Bioscience, Inc., is developing both research and therapeutic products using stem and endothelial cell related technologies.
Location: New York, NY
Foundation Cornell Technology Licensed: 2012
Aufbau Medical Innovations Ltd.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator: Center for Life Science Ventures
Aufbau Medical Innovations is an Irish Operating Company that develops novel therapeutics and diagnostics for ophthalmic diseases.
Location: Dublin, Ireland / Ithaca, NY
Foundation Cornell Technology Licensed: 2020
Convergent Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company’s proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University.
Location: New York
Foundation Cornell Technology Licensed: 1998
Faeth Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Faeth Therapeutics, Inc. is a data-driven, evidence-based healthcare company, with a mission to rethink the role of nutrition in the fight against cancer.
Location: San Francisco, CA
Foundation Cornell Technology Licensed: 2020
Hemogenyx Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Hemogenyx Therapeutics is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BMâ€) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.
Location: Buffalo, NY
Foundation Cornell Technology Licensed: 2014
IpiNovyx Bio Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
IpiNovyx is a biopharmaceutical company that aims to transform the ways autoimmune and inflammatory are treated through a reversable, ultra-potent and non-toxic approach.
Location: West Nyack, NY
Foundation Cornell Technology Licensed: 2021
Larkspur Biosciences, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Location: Boston, MA
Foundation Cornell Technology Licensed: 2021
LEXEO Therapeutics, LLC
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.
Location: New York, NY
Foundation Cornell Technology Licensed: 2020
Novita Pharmaceuticals, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Novita Pharmaceuticals, Inc. is a biopharmaceutical startup developing target-specific small molecule drugs to treat cancer metastasis. The company is currently focusing on patients with metastatic breast cancer.
Location: New York, NY
Foundation Cornell Technology Licensed: 2010
Ratio Therapeutics
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.
Location: New York, NY
Foundation Cornell Technology Licensed: 2021
SACYL Pharmaceuticals
Category: Therapeutics
Campus:
Incubator:
Sacyl Pharmaceuticals (SACYL) aims to develop potent soluble adenylyl cyclase (sAC) inhibitors into first-in-class systemic, non-hormonal, on-demand contraceptives for men and women with the goal to significantly contribute to increased use of modern contraceptives among couples to reduce unintended pregnancies, improving families’ health and well-being globally.
Location: Old Greenwich, CT
Foundation Cornell Technology Licensed: 2023
Sedec Therapeutics, Inc.
Category: Therapeutics
Campus: Ithaca
Incubator:
Sedec is a therapeutics company that aims to inhibit key factors in a subset of CD4+ T cells to decrease inflammation. This approach can be used to treat T cell-mediated autoimmune disorders, such as inflammatory bowel disease.
Location: Boston, MA
Foundation Cornell Technology Licensed: 2021
Stealth BioTherapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Stealth BioTherapeutics, Inc., is a clinical stage, biopharmaceutical company developing novel mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal and metabolic diseases. The company’s first clinical candidate, Bendaviaâ„¢, targets the mitochondria to treat cardio-renal and microvascular impairments.
Location: Newton, MA
Foundation Cornell Technology Licensed: 2006
UbiquiTx, Inc.
Category: Therapeutics
Campus: Ithaca
Incubator:
UbiquiTx, a spin-out from Cornell University and MIT, is focused on leveraging machine learning and protein engineering to develop programmable protein-modulating therapies. The company’s computational platform allows the designing of motif, mutant and PTM-specific peptides to pathogenic proteins from sequence alone based on known interactions found in nature.
Location: Cambridge, MA
Foundation Cornell Technology Licensed: 2022
Versatope Therapeutics, Inc.
Category: Therapeutics
Campus: Ithaca
Incubator:
Versatope Therapeutics is using exosomes (extracellular vesicles) derived from genetically engineered probiotics as a technology platform for the targeted delivery of large molecules used in vaccines, therapeutics and diagnostics. The company has worked with accelerators/incubators MassCONNECT, MassChallenge, and JLABS.
Location: Boston, MA
Foundation Cornell Technology Licensed: 2018
Vescor Therapeutics Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Vescor Therapeutics Inc., is an immuno-oncology company that is developing new therapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment. Chronic activation of this stress response is linked to poor outcomes in multiple cancers, such as ovarian cancer, triple-negative breast cancer, pancreatic adenocarcinoma and glioblastoma. The company was founded based on intellectual property generated from Weill Cornell Medicine and is developing small molecule therapeutics that inhibit the enzyme IRE1α.
Location: New York, NY
Foundation Cornell Technology Licensed: 2024
Volastra Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers. The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.
Location: New York, NY
Foundation Cornell Technology Licensed: 2019
XyloCor Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.
Location: New York, NY
Foundation Cornell Technology Licensed: 2015
